Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
Public ClinicalTrials.gov record NCT02918279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.
Study identification
- NCT ID
- NCT02918279
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 251 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2016 (Actual)
- Primary completion
- Feb 14, 2019 (Actual)
- Completion
- Aug 8, 2019 (Actual)
- Last update posted
- Apr 27, 2020
2016 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Meridian | Idaho | 83646 | — |
| Novo Nordisk Investigational Site | Baton Rouge | Louisiana | 70808-4124 | — |
| Novo Nordisk Investigational Site | Baltimore | Maryland | 21229 | — |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55455 | — |
| Novo Nordisk Investigational Site | Buffalo | New York | 14222 | — |
| Novo Nordisk Investigational Site | Columbus | Ohio | 43213 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45406 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45419 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15224 | — |
| Novo Nordisk Investigational Site | Charleston | South Carolina | 29425 | — |
| Novo Nordisk Investigational Site | Goose Creek | South Carolina | 29445 | — |
| Novo Nordisk Investigational Site | Greenville | South Carolina | 29615 | — |
| Novo Nordisk Investigational Site | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02918279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2020 · Synced Oct 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02918279 live on ClinicalTrials.gov.